Do analysts prefer BDSX or MRAI?

Biodesix currently has a consensus price target of $31.33, suggesting a potential upside of 5.68%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, BDSX or MRAI?

Marpai has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.53 -$35.26M -$3.17 N/A Marpai $34.87M 2.44 -$28.75M -$0.77 N/A

Is BDSX or MRAI more profitable?

Biodesix has a net margin of -26.97% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Marpai -85.70% N/A -100.23%

Do analysts prefer INFU or MRAI?

InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 38.65%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts clearly believe InfuSystem is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InfuSystem 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, INFU or MRAI?

InfuSystem has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.78 $870K $0.41 30.79 Marpai $34.87M 2.44 -$28.75M -$0.77 N/A

Is INFU or MRAI more profitable?

InfuSystem has a net margin of 1.12% compared to Marpai's net margin of -85.70%. InfuSystem's return on equity of 2.78% beat Marpai's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Marpai -85.70% N/A -100.23%

Do analysts prefer XGN or MRAI?

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 10.38%. Given Exagen's stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, XGN or MRAI?

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 3.17 -$19.95M -$0.81 N/A Marpai $34.87M 2.44 -$28.75M -$0.77 N/A

Is XGN or MRAI more profitable?

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Marpai -85.70% N/A -100.23%

Do analysts recommend MRAI or LFMD?

LifeMD has a consensus price target of $7.57, indicating a potential upside of 157.09%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has stronger valuation & earnings, MRAI or LFMD?

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 2.44 -$28.75M -$0.77 N/A LifeMD $194.05M 0.73 $14.35M -$0.05 N/A

Is MRAI or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% LifeMD 0.10% -168.23% -31.27%

Do analysts prefer MRAI or AIRS?

AirSculpt Technologies has a consensus price target of $4.50, indicating a potential upside of 124.44%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AirSculpt Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Marpai (MRAI) Competitors

$3.16 +0.11 (+3.61%)

As of 11:12 AM Eastern

Compare

MRAI vs. BDSX, INFU, XGN, LFMD, and AIRS

Should you buy Marpai stock or one of its competitors? Marpai's main competitors and comparable companies include Biodesix (BDSX), InfuSystem (INFU), Exagen (XGN), LifeMD (LFMD), and AirSculpt Technologies (AIRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Marpai compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Biodesix has a net margin of -26.97% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Marpai	-85.70%	N/A	-100.23%

Biodesix currently has a consensus price target of $31.33, suggesting a potential upside of 5.68%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marpai has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.53	-$35.26M	-$3.17	N/A
Marpai	$34.87M	2.44	-$28.75M	-$0.77	N/A

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biodesix has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Marpai has a beta of 4.73, meaning that its share price is 373% more volatile than the broader market.

In the previous week, Biodesix had 7 more articles in the media than Marpai. MarketBeat recorded 7 mentions for Biodesix and 0 mentions for Marpai. Biodesix's average media sentiment score of 0.17 beat Marpai's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Overall Sentiment
Biodesix	Neutral
Marpai	Neutral

Summary

Biodesix beats Marpai on 10 of the 17 factors compared between the two stocks.

How does Marpai compare to InfuSystem?

InfuSystem (NYSE:INFU) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

InfuSystem has a net margin of 1.12% compared to Marpai's net margin of -85.70%. InfuSystem's return on equity of 2.78% beat Marpai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Marpai	-85.70%	N/A	-100.23%

InfuSystem has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.78	$870K	$0.41	30.79
Marpai	$34.87M	2.44	-$28.75M	-$0.77	N/A

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InfuSystem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Marpai has a beta of 4.73, meaning that its stock price is 373% more volatile than the broader market.

InfuSystem presently has a consensus target price of $17.50, suggesting a potential upside of 38.65%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts clearly believe InfuSystem is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, InfuSystem had 5 more articles in the media than Marpai. MarketBeat recorded 5 mentions for InfuSystem and 0 mentions for Marpai. InfuSystem's average media sentiment score of 0.25 beat Marpai's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Neutral
Marpai	Neutral

Summary

InfuSystem beats Marpai on 13 of the 16 factors compared between the two stocks.

How does Marpai compare to Exagen?

Exagen (NASDAQ:XGN) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 10.38%. Given Exagen's stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Exagen had 5 more articles in the media than Marpai. MarketBeat recorded 5 mentions for Exagen and 0 mentions for Marpai. Exagen's average media sentiment score of 0.92 beat Marpai's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Marpai	Neutral

Exagen has higher revenue and earnings than Marpai. Exagen is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	3.17	-$19.95M	-$0.81	N/A
Marpai	$34.87M	2.44	-$28.75M	-$0.77	N/A

Exagen has a net margin of -26.61% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Marpai	-85.70%	N/A	-100.23%

75.3% of Exagen shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Marpai has a beta of 4.73, indicating that its stock price is 373% more volatile than the broader market.

Summary

Exagen beats Marpai on 12 of the 17 factors compared between the two stocks.

How does Marpai compare to LifeMD?

Marpai (NASDAQ:MRAI) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

49.8% of Marpai shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LifeMD has a net margin of 0.10% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has higher revenue and earnings than Marpai. LifeMD is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.44	-$28.75M	-$0.77	N/A
LifeMD	$194.05M	0.73	$14.35M	-$0.05	N/A

Marpai has a beta of 4.73, meaning that its share price is 373% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

LifeMD has a consensus price target of $7.57, indicating a potential upside of 157.09%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, LifeMD had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for LifeMD and 0 mentions for Marpai. LifeMD's average media sentiment score of 0.60 beat Marpai's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
LifeMD	Positive

Summary

LifeMD beats Marpai on 10 of the 16 factors compared between the two stocks.

How does Marpai compare to AirSculpt Technologies?

Marpai (NASDAQ:MRAI) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

49.8% of Marpai shares are held by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, AirSculpt Technologies had 5 more articles in the media than Marpai. MarketBeat recorded 5 mentions for AirSculpt Technologies and 0 mentions for Marpai. AirSculpt Technologies' average media sentiment score of 0.36 beat Marpai's score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
AirSculpt Technologies	Neutral

AirSculpt Technologies has a net margin of -7.79% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat AirSculpt Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
AirSculpt Technologies	-7.79%	-5.83%	-2.88%

AirSculpt Technologies has higher revenue and earnings than Marpai. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	2.44	-$28.75M	-$0.77	N/A
AirSculpt Technologies	$151.82M	0.95	-$11.67M	-$0.18	N/A

AirSculpt Technologies has a consensus price target of $4.50, indicating a potential upside of 124.44%. Given AirSculpt Technologies' stronger consensus rating and higher probable upside, analysts plainly believe AirSculpt Technologies is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Marpai has a beta of 4.73, suggesting that its stock price is 373% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market.

Summary

AirSculpt Technologies beats Marpai on 10 of the 15 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.92M	$9.69B	$7.24B	$13.12B
Dividend Yield	N/A	2.59%	2.52%	12.57%
P/E Ratio	-1.20	34.80	274.66	25.73
Price / Sales	2.44	5.07	686.13	110.82
Price / Cash	N/A	122.11	77.80	52.76
Price / Book	-1.84	5.21	10.45	6.32
Net Income	-$28.75M	$315.70M	$3.48B	$359.89M
7 Day Performance	-4.82%	1.10%	-1.05%	-0.23%
1 Month Performance	51.20%	1.07%	-4.36%	-4.16%
1 Year Performance	175.98%	18.26%	16.36%	6.00%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$3.16 +3.6%	N/A	+166.4%	$84.92M	$34.87M	N/A	150
BDSX Biodesix	3.0847 of 5 stars	$28.72 +0.6%	$31.33 +9.1%	+250.4%	$302.93M	$88.50M	N/A	334
INFU InfuSystem	3.639 of 5 stars	$12.46 +0.1%	$16.67 +33.8%	+23.8%	$251.47M	$143.34M	207.70	473	News Coverage
XGN Exagen	3.3443 of 5 stars	$7.76 -0.2%	$9.63 +24.0%	-18.9%	$187.20M	$66.57M	N/A	220
LFMD LifeMD	2.9844 of 5 stars	$3.28 +2.1%	$7.57 +131.0%	-54.5%	$158.10M	$194.05M	N/A	384

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors